[go: up one dir, main page]

Wolf et al., 1985 - Google Patents

Antithrombin Milano: a new variant with monomeric and dimeric inactive antithrombin III

Wolf et al., 1985

View HTML
Document ID
6546840502465716063
Author
Wolf M
Boyer C
Tripodi A
Meyer D
Larrieu M
Mannucci P
Publication year

External Links

Snippet

A qualitative defect of antithrombin III (AT III) has been demonstrated over three generations in eight members of an Italian family by the discrepancy between a normal amount of antigen and decreased antithrombin and anti-Xa activity in the presence or in the absence of …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates

Similar Documents

Publication Publication Date Title
Kruithof et al. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma
Fair et al. Combined functional and immunochemical analysis of normal and abnormal human factor X
Tuszynski et al. Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation.
KRATZIN et al. Structural relationship of an apolipoprotein (a) phenotype (570 kDa) to plasminogen: homologous kringle domains are linked by carbohydrate-rich regions
Schwarz et al. Plasma protein S deficiency in familial thrombotic disease
Scott et al. Inactivation of factor XIa by plasma protease inhibitors: predominant role of α 1-protease inhibitor and protective effect of high molecular weight kininogen
Canfield et al. Evidence of normal functional levels of activated protein C inhibitor in combined Factor V/VIII deficiency disease.
Borg et al. Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser.
Tran et al. Purification and partial characterization of a hereditary abnormal antithrombin III fraction of a patient with recurrent thrombophlebitis
Boyer et al. Homozygous variant of antithrombin III: AT III Fontainebleau
Wolf et al. Antithrombin Milano: a new variant with monomeric and dimeric inactive antithrombin III
Okajima et al. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto
Rimon et al. Identification of a factor IX/IXa binding protein on the endothelial cell surface.
Stathakis et al. Characterization of cryofibrinogen isolated from patients’ plasma
Yoshida et al. An apparently higher molecular weight gamma-chain variant in a new congenital abnormal fibrinogen Tochigi characterized by the replacement of gamma arginine-275 by cysteine
Carlson et al. Isolation and partial characterization of two distinct types of antithrombin III from rabbit
Aiach et al. A functional abnormal antithrombin III (AT III) deficiency: AT III Charleville
Tsianos et al. Soluble fibrin complexes and fibrinogen heterogeneity in diabetes mellitus
Howarth et al. Antithrombin III “Northwick Park”: a variant antithrombin with normal affinity for heparin but reduced heparin cofactor activity
Koide et al. Isolation and characterization of a hereditary abnormal antithrombin III ‘antithrombin III toyama’
Lane et al. Antithrombin III Glasgow: a variant with increased heparin affinity and reduced ability to inactivate thrombin, associated with familial thrombosis
Kirby et al. Degradation of bovine factor VIII by plasmin and trypsin
Jørgensen et al. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding
Shigekiyo et al. Protein S Tokushima: an abnormal protein S found in a Japanese family with thrombosis
Girolami et al. Antithrombin III Trento: A ‘New’Congenital AT III Abnormality with a Peculiar Crossed-Immunoelectrophoretic Pattern in the Absence of Heparin